Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 257-270

  Weitz, Jeffrey I ^a,b   Eikelboom, John ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulant; Atrial fibrillation; Edoxaban; Non vitamin K oral anticoagulants

Indexed keywords

APIXABAN; CREATININE; CYTOCHROME P450 3A4; DABIGATRAN; EDOXABAN; MULTIDRUG RESISTANCE PROTEIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BIOAVAILABILITY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DECISION MAKING; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; MODERATE RENAL IMPAIRMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; CARDIOVASCULAR DISEASES; CHEMISTRY; EMBOLISM; FEMALE; INTRACRANIAL HEMORRHAGES; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DABIGATRAN; EMBOLISM; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; PYRAZOLES; PYRIDINES; PYRIDONES; RESEARCH DESIGN; RIVAROXABAN; STROKE; THIAZOLES; WARFARIN;

EID: 84957111698     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0181     Document Type: Review

References (79)

1. Wolf PA, et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–988.
2. McGrath ER, et al. Association of atrial fibrillation with mortality and disability after ischaemic stroke. Neurology 2013; 81: 825–832.
3. Rahman F, et al. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014; 11: 639–654.
4. Go AS, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292.
5. January CT, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e76.
6. Camm AJ, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.
7. You JJ, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e531S-575S.
8. Ogilvie IM, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010; 123: 638–645 e634.
9. Ansell J, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S.
10. Baker WL, et al. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244–252.
11. Cotte FE, et al. Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries. Clin Ther 2014; 36: 1160–1168.
12. Biskupiak J, et al. Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation. J Manag Care Pharm 2013; 19: 789–798.
13. Schulman S, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost 2010; 8: 2192–2200.
14. Ruff CT, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.
15. Stangier J, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292–303.
16. Frost C, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: 776–786.
17. Kubitza D, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412–421.
18. Ogata K, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010; 50: 743–753.
19. Mendell J, et al. The Effect of Rifampin on the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Edoxaban in Healthy Subjects. J Thromb Haemost 2014; 12: Abstract COA26.
20. Mendell J, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013; 13: 331–342.
21. Blech S, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386–399.
22. Raghavan N, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74–81.
23. Weinz C, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009; 37: 1056–1064.
24. Bathala MS, et al. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012; 40: 2250–2255.
25. Matsushima N, et al. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharm Drug Dev 2013; 2: 358–366.
26. ELIQUIS® (apixaban) tablets for oral use. Full Prescribing Information. Bristol- Myers Squibb Company, Princeton, NJ, USA and Pfizer Inc, NY, NY, USA. 2014.
27. PRADAXA® (dabigatran etexilate mesylate). Full Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. 2015.
28. XARELTO® (rivaroxaban) tablets. Full prescribing information. Janssen Pharmaceuticals, Titusville, NJ, USA. 2015.
29. Mikkaichi T, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug’s disposition. Drug Metab Dispos 2014; 42: 520–528.
30. Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
31. Patel MR, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.
32. Granger CB, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
33. Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093–2104.
34. Weitz JI, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; 104: 633–641.
35. Salazar DE, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012; 107: 925–936.
36. Feinberg WM, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469–473.
37. Lopes RD, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331–339.
38. Hylek EM, et al. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 2008; 39: 3009–3014.
39. Giugliano RP, et al. Reduction in bleeding with edoxaban vs warfarin linked to lower all-cause mortality in 21,105 pateints randomized in the ENGAGE AFTIMI 48 trial. Eur Heart J 2015; 35: 851–1187; Abstract 4874.
40. Cohen E, et al. A longitudinal assessment of the natural rate of decline in renal function with age. J Nephrol 2014; 27: 635-641.
41. Go AS, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363–1369.
42. Hijazi Z, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961–970.
43. Fox KA, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394.
44. European Medicines Agency: Xarelto (rivaroxaban) Summary of product characteristics. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&mid=WC0b01ac058001d124. Accessed December 10, 2014.
45. Xarelto [monograph]. Toronto, Ontario. Bayer Inc. 2015. Available at: http://www.bayer.ca/en/products/healthcare-product-search/. Accessed July 30, 2015.
46. Hohnloser SH, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821–2830.
47. SAVAYSATM (edoxaban) tablets for oral use. Full Prescribing Information. Parsippany, NJ. Daiichi Sankyo Inc. 2015.
48. Robert-Ebadi H, et al. Use of anticoagulants in elderly patients: practical recommendations. Clin Interv Aging 2009; 4: 165–177.
49. Eikelboom JW, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–2372.
50. PRADAXA: Indications, dosing and contraindications. Available at: http://www.boehringer-ingelheim.com/products/prescription_medicines/pradaxa/home/indications-dosing.html. Boehringer Ingelheim Gmbh. 2014. Accessed July 10, 2015.
51. Wang L, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010; 38: 448–458.
52. Center for Drug Evaluation and Research (2012). Guidance for industry – Drug Interaction Studies. US Food and Drug Administration. Rockville, MD. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.
53. Zalesak M, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013; 6: 567–574.
54. Nelson WW, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin 2014; 30: 2461–2469.
55. Lip GY, et al. Patient outcomes using the European label for dabigatran. A posthoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933–942.
56. Vrijens B, Urquhart J. From monitoring to vigilance about patient adherence to new oral anticoagulants. Europace 2014; 16: 149.
57. Heidbuchel H, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625–651.
58. Connolly SJ, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.
59. Ezekowitz MD, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010; 122: 2246–2253.
60. Mahaffey KW, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013; 158: 861–868.
61. Garcia DA, et al. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J 2013; 166: 549–558.
62. O’Donoghue ML, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J 2015; 36: 1470–1477.
63. Mega JL, et al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385: 2280–2287.
64. Abraham NS, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Br Med J 2015; 350: h1857.
65. Desai J, et al. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110: 205–212.
66. Boehringer Ingelheim’s Investigational Antidote for Pradaxa(R) (dabigatran etexilate mesylate) Receives FDA Breakthrough Therapy Designation [press release]. Ridgefield, CT: Boehringer Ingelheim; June 26, 2014. http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/06–26–14-boehringer-ingelheim-investigational-antidote-pradaxa-dabigatran-etexilate-mesylate-fda-breakthrough-therapy-designation.html. Accessed October 6, 2014.
67. Pollack CV, Jr., et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; Epub ahead of print.
68. Crowther M, et al. ANNEXA(TM)-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alpha (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors. AHA Scientific Session 2014; 2014; Chicago, IL; 2014.
69. Lu G, et al. In Vitro Characterization of Andexanet Alpha (PRT064445), a Specific fXa Inhibitor Antidote versus Aripazine (PER977), a Non-specific Reversal Agent. Circulation 2014; 130: A12218.
70. Ansell JE, et al. Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. N Engl J Med 2014; Epub ahead of print.
71. Eerenberg ES, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–1579.
72. Levi M, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12: 1428–1436.
73. Marlu R, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217–224.
74. Zahir H, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2014; Epub ahead of print.
75. European Medicines Agency: Eliquis (apixaban) Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed December 10, 2014.
76. European Medicines Agency. Pradaxa (dabigatran). European public assessment report (EPAR) Product Information. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (updated March 19, 2014) Accessed July 30, 2015.
77. ELIQUIS [monograph]. Montreal, Quebec: Bristol-Myers Squibb Canada. 2015. Availlable at: http://www.pfizer.ca/en/our_products/products/monograph/313. Accessed May 15, 2015.
78. PRADAXA [monograph]. Burlington, Ontario: Boehringer-Ingelheim Canada Ltd. 2015. Available at: http://boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PradaxaPMEN.pdf. Accessed July 30, 2015.
79. LIXIANA®(edoxaban). Package Leaflet. Daiichi Sankyo Europe GmbH. Munich, Germany. 2015. Available at: https://www.medicines.org.uk/emc/PIL.30504.latest.pdf. Accessed July 30, 2015.